$HBIO
HARVARD BIOSCIENCE INC

2013 Q3 Form 10-Q Financial Statement

#000117184313004541 Filed on November 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $25.14M $26.10M
YoY Change -3.7% -1.05%
Cost Of Revenue $13.84M $14.14M
YoY Change -2.1% -2.54%
Gross Profit $11.30M $11.97M
YoY Change -5.6% 0.77%
Gross Profit Margin 44.95% 45.85%
Selling, General & Admin $8.820M $9.502M
YoY Change -7.18% 6.51%
% of Gross Profit 78.06% 79.39%
Research & Development $1.934M $1.861M
YoY Change 3.92% 19.76%
% of Gross Profit 17.12% 15.55%
Depreciation & Amortization $960.0K $1.020M
YoY Change -5.88% -8.11%
% of Gross Profit 8.5% 8.52%
Operating Expenses $10.89M $10.81M
YoY Change 0.67% -7.25%
Operating Profit $414.0K $1.156M
YoY Change -64.19% 425.45%
Interest Expense $276.0K $147.0K
YoY Change 87.76% -31.94%
% of Operating Profit 66.67% 12.72%
Other Income/Expense, Net -$358.0K -$178.0K
YoY Change 101.12% -47.34%
Pretax Income $56.00K $978.0K
YoY Change -94.27% -928.81%
Income Tax $105.0K $278.0K
% Of Pretax Income 187.5% 28.43%
Net Earnings -$984.0K -$133.0K
YoY Change 639.85% -575.0%
Net Earnings / Revenue -3.91% -0.51%
Basic Earnings Per Share -$0.03 -$0.01
Diluted Earnings Per Share -$0.03 -$0.01
COMMON SHARES
Basic Shares Outstanding 30.57M shares 28.80M shares
Diluted Shares Outstanding 30.57M shares 28.80M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.90M $20.30M
YoY Change 81.77% 25.31%
Cash & Equivalents $36.90M $20.29M
Short-Term Investments
Other Short-Term Assets $1.600M $2.996M
YoY Change -46.6% 10.23%
Inventory $18.00M $17.99M
Prepaid Expenses
Receivables $13.40M $13.60M
Other Receivables $4.000M $3.000M
Total Short-Term Assets $73.90M $58.76M
YoY Change 25.76% 0.58%
LONG-TERM ASSETS
Property, Plant & Equipment $4.600M $4.097M
YoY Change 12.28% 32.93%
Goodwill $35.95M
YoY Change 0.57%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.80M $67.00K
YoY Change 19004.48% -72.76%
Total Long-Term Assets $74.40M $71.82M
YoY Change 3.6% 4.78%
TOTAL ASSETS
Total Short-Term Assets $73.90M $58.76M
Total Long-Term Assets $74.40M $71.82M
Total Assets $148.3M $130.6M
YoY Change 13.57% 2.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.700M $4.141M
YoY Change 13.5% -21.35%
Accrued Expenses $4.400M $3.766M
YoY Change 16.83% -0.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.000M
YoY Change
Total Short-Term Liabilities $13.50M $9.531M
YoY Change 41.64% -6.7%
LONG-TERM LIABILITIES
Long-Term Debt $20.50M $15.30M
YoY Change 33.99% -6.16%
Other Long-Term Liabilities $6.200M $4.900M
YoY Change 26.53% 40.0%
Total Long-Term Liabilities $26.70M $15.30M
YoY Change 74.51% -6.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.50M $9.531M
Total Long-Term Liabilities $26.70M $15.30M
Total Liabilities $40.50M $30.22M
YoY Change 34.03% -2.49%
SHAREHOLDERS EQUITY
Retained Earnings -$78.46M
YoY Change -2.37%
Common Stock $382.0K $194.2M
YoY Change -99.8% 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 7.746M shares 7.746M shares
Shareholders Equity $107.8M $100.4M
YoY Change
Total Liabilities & Shareholders Equity $148.3M $130.6M
YoY Change 13.57% 2.84%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$984.0K -$133.0K
YoY Change 639.85% -575.0%
Depreciation, Depletion And Amortization $960.0K $1.020M
YoY Change -5.88% -8.11%
Cash From Operating Activities $1.430M $2.510M
YoY Change -43.03% 107.44%
INVESTING ACTIVITIES
Capital Expenditures -$510.0K -$540.0K
YoY Change -5.56% 80.0%
Acquisitions
YoY Change
Other Investing Activities $1.780M $30.00K
YoY Change 5833.33% -100.58%
Cash From Investing Activities $1.270M -$510.0K
YoY Change -349.02% -90.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -750.0K -740.0K
YoY Change 1.35% 8.82%
NET CHANGE
Cash From Operating Activities 1.430M 2.510M
Cash From Investing Activities 1.270M -510.0K
Cash From Financing Activities -750.0K -740.0K
Net Change In Cash 1.950M 1.260M
YoY Change 54.76% -125.56%
FREE CASH FLOW
Cash From Operating Activities $1.430M $2.510M
Capital Expenditures -$510.0K -$540.0K
Free Cash Flow $1.940M $3.050M
YoY Change -36.39% 101.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-84000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.98
hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-57000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
107835000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
276000 USD
CY2013Q3 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
10000 USD
CY2013Q3 us-gaap Restructuring Charges
RestructuringCharges
96000 USD
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3505000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
41652000 USD
us-gaap Gross Profit
GrossProfit
35665000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13790000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15996000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5856000 USD
us-gaap Restructuring Charges
RestructuringCharges
51000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1955000 USD
us-gaap Revenues
Revenues
77317000 USD
CY2013Q3 us-gaap Revenues
Revenues
25137000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
263000 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
253000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
277000 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21225000 USD
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38530630 shares
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9901000 USD
CY2012Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1276000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12950000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
196634000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000 USD
CY2012Q4 us-gaap Assets
Assets
133484000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133484000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
194000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4680000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
482000 USD
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30785123 shares
CY2013Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
382000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
728000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
370000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
104213000 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
3000000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
0 USD
CY2012Q4 us-gaap Liabilities
Liabilities
29271000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77260000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4863000 USD
us-gaap Operating Expenses
OperatingExpenses
37648000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1983000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-74000 USD
us-gaap Interest Expense
InterestExpense
650000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
28000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-783000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2766000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1410000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2013Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13833000 USD
CY2012Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.04
CY2012Q4 us-gaap Assets Current
AssetsCurrent
58972000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4551000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
10770000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
36200000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
6143000 USD
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37123705 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29378198 shares
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
67000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-628000 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
11304000 USD
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4414000 USD
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
594642 shares
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1934000 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1054000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-357000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1411000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-433000 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2012Q3 us-gaap Revenues
Revenues
26104000 USD
CY2012Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14110000 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
11994000 USD
CY2012Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4670000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4832000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1861000 USD
CY2012Q3 us-gaap Restructuring Charges
RestructuringCharges
29000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-257000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-124000 USD
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
43913000 USD
us-gaap Revenues
Revenues
82922000 USD
us-gaap Gross Profit
GrossProfit
39009000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14182000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14593000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5549000 USD
us-gaap Restructuring Charges
RestructuringCharges
166000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2071000 USD
us-gaap Operating Expenses
OperatingExpenses
36561000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
2448000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-86000 USD
us-gaap Interest Expense
InterestExpense
447000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
37000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-294000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-790000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1658000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
490000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-983000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-133000 USD
us-gaap Net Income Loss
NetIncomeLoss
-1074000 USD
us-gaap Net Income Loss
NetIncomeLoss
1168000 USD
CY2013Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2387000 USD
CY2012Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1444000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
497000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1404000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1356000 USD
CY2012Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
988000 USD
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
506000 USD
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5314000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
12358000 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
681000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
12073000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-79000 USD
CY2012Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-29000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
147000 USD
CY2012Q3 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
11000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-178000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1311000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.03
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-1089000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
12049000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2290000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16250000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12547000 USD
us-gaap Interest Paid
InterestPaid
534000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2373000 USD
us-gaap Depreciation
Depreciation
930000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
28000 USD
hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
139000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-23000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1841000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-861000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
107000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1196000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-21000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-342000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
58000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-494000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6656000 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-1151000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
36000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2863000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
461000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-539000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
230000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2369000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20285000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17916000 USD
us-gaap Interest Paid
InterestPaid
411000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1244000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1142000 USD
hbio Non Cash Restructuring Credit Charge
NonCashRestructuringCreditCharge
51000 USD
hbio Non Cash Restructuring Credit Charge
NonCashRestructuringCreditCharge
-13000 USD
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0 USD
hbio Additions To Catalog Costs
AdditionsToCatalogCosts
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1500000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-577000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2156000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.03
CY2012Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.04
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2012Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.00
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.04
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.04
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2012Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2013Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-978000 USD
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-5000 USD
CY2013Q3 us-gaap Discontinued Operation Amount Of Other Income Loss From Disposition Of Discontinued Operation Net Of Tax
DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTax
-5000 USD
CY2012Q3 us-gaap Discontinued Operation Amount Of Other Income Loss From Disposition Of Discontinued Operation Net Of Tax
DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTax
0 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-133000 USD
us-gaap Discontinued Operation Amount Of Other Income Loss From Disposition Of Discontinued Operation Net Of Tax
DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTax
282000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
282000 USD
us-gaap Discontinued Operation Amount Of Other Income Loss From Disposition Of Discontinued Operation Net Of Tax
DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTax
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1168000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2000000 USD
us-gaap Depreciation
Depreciation
990000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000 USD
hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
84000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
69000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
29000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1712000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-948000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
227000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1015000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-15000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
406000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
615000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
143000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2811000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
66000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2013Q1 hbio Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed
MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed
0.5 pure
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8644009 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6060144 shares
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
583000 USD
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
383000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
41283000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
41133000 USD
CY2013Q3 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
37601000 USD
CY2012Q4 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
37476000 USD
us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
118000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2600000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2400000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2100000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2000000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1800000 USD
CY2013Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7957000 USD
CY2013Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
806000 USD
CY2013Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
9265000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8023000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
731000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9008000 USD
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
25597 shares
CY2013Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
763000 USD
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
958000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2000000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7227774 shares
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-181000 USD
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
616000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2013Q3 us-gaap Debt Issuance Costs
DebtIssuanceCosts
0 USD
CY2013Q3 us-gaap Secured Debt
SecuredDebt
23500000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1500000 USD
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
440000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
292000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
1709000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
629000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3978000 USD
us-gaap Derivatives Methods Of Accounting Hedging Derivatives
DerivativesMethodsOfAccountingHedgingDerivatives
<p style='margin-top:0pt; margin-bottom:7pt'><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;margin-left:-4.5px;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">Derivatives</font></p><p style='margin-top:0pt; margin-bottom:10pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The Company uses interest</font><font style="font-family:Times New Roman;font-size:10pt;">-rate</font><font style="font-family:Times New Roman;font-size:10pt;">-related derivative instruments to manage its exposure related to changes in interest rates on its variable</font><font style="font-family:Times New Roman;font-size:10pt;">-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. For derivatives designated in hedging relationships, changes in the fair value are either offset through earnings against the change in fair value of the hedged item attributable to the risk being hedged or recognized in accumulated other comprehensive income (&#8220;AOCI&#8221;), to the extent the derivative is effective at offsetting the changes in cash flows being hedged until the hedged item affects earnings.</font></p><p style='margin-top:0pt; margin-bottom:10pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:13.5px;">The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk</font><font style="font-family:Times New Roman;font-size:10pt;">-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments </font><font style="font-family:Times New Roman;font-size:10pt;">that are designated and qualify as part of a cash flow hedgin</font><font style="font-family:Times New Roman;font-size:10pt;">g relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.</font></p><p style='margin-top:0pt; margin-bottom:10pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:13.5px;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The Company discontinues hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedged risk, the derivative expires or is sold, terminated, or exercised, the cash flow hedge is de</font><font style="font-family:Times New Roman;font-size:10pt;">-</font><font style="font-family:Times New Roman;font-size:10pt;">designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge.</font></p><p style='margin-top:0pt; margin-bottom:10pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:9px;"> </font><font style="font-family:Times New Roman;font-size:10pt;">In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company discontinues hedge accounting and recognizes immediately in earnings gains and losses that were accumulated in other comprehensive income related to the hedging relationship.</font></p>
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<p style='margin-top:13.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:-0.0500000000000007px;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements </font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"> </font><font style="font-family:Times New Roman;font-size:10pt;">In July 2013, the FASB issued ASU 2013-11, &#8220;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss </font><font style="font-family:Times New Roman;font-size:10pt;">Carryforward</font><font style="font-family:Times New Roman;font-size:10pt;">, a Similar Tax Loss, or a Tax Credit </font><font style="font-family:Times New Roman;font-size:10pt;">Carryforward</font><font style="font-family:Times New Roman;font-size:10pt;"> Exists&#8221;, which requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) </font><font style="font-family:Times New Roman;font-size:10pt;">carryforward</font><font style="font-family:Times New Roman;font-size:10pt;">, or similar tax loss or tax credit </font><font style="font-family:Times New Roman;font-size:10pt;">carryforward</font><font style="font-family:Times New Roman;font-size:10pt;">, rather than as a liability when the uncertain tax position would reduce the NOL or other </font><font style="font-family:Times New Roman;font-size:10pt;">carryforward</font><font style="font-family:Times New Roman;font-size:10pt;"> under the tax law. The ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company believes the adoption of this new guidance will not have a material impact on its consolidated results of operations or financial position.</font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"> In February 2013, the FASB issued additional guidance in ASU&#160;2013-02, </font><font style="font-family:Times New Roman;font-size:10pt;">&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">Reporting A</font><font style="font-family:Times New Roman;font-size:10pt;">mounts </font><font style="font-family:Times New Roman;font-size:10pt;">R</font><font style="font-family:Times New Roman;font-size:10pt;">eclassified </font><font style="font-family:Times New Roman;font-size:10pt;">O</font><font style="font-family:Times New Roman;font-size:10pt;">ut</font><font style="font-family:Times New Roman;font-size:10pt;"> of </font><font style="font-family:Times New Roman;font-size:10pt;">A</font><font style="font-family:Times New Roman;font-size:10pt;">ccumulated </font><font style="font-family:Times New Roman;font-size:10pt;">O</font><font style="font-family:Times New Roman;font-size:10pt;">ther </font><font style="font-family:Times New Roman;font-size:10pt;">C</font><font style="font-family:Times New Roman;font-size:10pt;">omprehensive </font><font style="font-family:Times New Roman;font-size:10pt;">I</font><font style="font-family:Times New Roman;font-size:10pt;">ncome</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221; The new guidance requires an entity to present the effects on net income line items of significant amounts reclassified out of accumulated other comprehensive income, but only if the item reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. The Company shall provide this information either on the face of the statements or in the notes to the consolidated financial statements. The guidance is effective for fiscal years beginning after December&#160;15, 2012. The adoption of this new guidance did not have a material impact on our consolidated results of operations or financial position.</font></p><p style='margin-top:9pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:9pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:4.5pt; margin-bottom:0pt'>&#160;</p>
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21936000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19908000 USD
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
241000 USD
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
600000 USD
CY2013Q3 us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
CY2012Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
206000 USD
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
235000 USD
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
700000 USD
CY2011Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
144000 USD
CY2012 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-136000 USD
CY2012 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
214000 USD
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
222000 USD
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-89000 USD
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
160000 USD
CY2013Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
293000 USD
CY2013Q3 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
84000 USD
CY2013Q3 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
209000 USD
CY2013Q3 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
137000 USD
CY2013Q3 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-65000 USD
CY2013Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
221000 USD
CY2012Q3 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
83000 USD
CY2012Q3 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
214000 USD
CY2012Q3 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
147000 USD
CY2012Q3 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-56000 USD
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
414000 USD
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-156000 USD
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
583000 USD
CY2013Q3 us-gaap Defined Benefit Plan Estimated Future Employer Contributions In Current Fiscal Year
DefinedBenefitPlanEstimatedFutureEmployerContributionsInCurrentFiscalYear
200000 USD
CY2012Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
CY2013Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
300000 USD
CY2012Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
5900000 USD
CY2013Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
5900000 USD
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
700000 USD
hbio Estimated Rental Expenses Current Year
EstimatedRentalExpensesCurrentYear
1200000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1197000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1048000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
743000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
455000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
159000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
69000 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3671000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1972956 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8078509 shares
CY2012Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
826388 shares
hbio Stock Options And Restricted Stock Units Issued
StockOptionsAndRestrictedStockUnitsIssued
950665 shares
hbio Fungible Share Adjustment For Restricted Stock Units Granted
FungibleShareAdjustmentForRestrictedStockUnitsGranted
-98182 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-1924264 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
24169 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
-5.73
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6060144 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2091289 shares
CY2013Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.37
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
428885 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
677193 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
124277 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
-233530 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.08
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.97
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
-920489 shares
hbio Stock Options And Restricted Stock Units Cancelled
StockOptionsAndRestrictedStockUnitsCancelled
1059544 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-139055 shares
hbio Fungible Share Adjustment For Restricted Stock Units Cancelled
FungibleShareAdjustmentForRestrictedStockUnitsCancelled
83467 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.47
us-gaap Share Based Compensation
ShareBasedCompensation
2373000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.572
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0118
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5509
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0080
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30574815 shares
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30574815 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28797887 shares
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28797887 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30154788 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30154788 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28758621 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29353263 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5812794 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85
CY2013Q3 hbio Employee Stock Purchase Plan Shares Authorized
EmployeeStockPurchasePlanSharesAuthorized
750000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
27305 shares
CY2012Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.64
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
497708 shares
us-gaap Deferred Compensation Arrangement With Individual Maximum Contractual Term
DeferredCompensationArrangementWithIndividualMaximumContractualTerm
10 years
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2013Q3 hbio Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan
IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan
250000 shares
CY2009Q3 hbio Previous Approved Credit Facility
PreviousApprovedCreditFacility
20000000 USD
CY2013Q1 hbio Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold
LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold
6000000 USD
CY2013Q4 hbio Additional Stock Options Issued Due To Hart Spin Off
AdditionalStockOptionsIssuedDueToHartSpinOff
1.7 shares
CY2013Q1 hbio Lender Approval To Fund Acquisition With Equity In Excess Of Threshold
LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold
10000000 USD
us-gaap Debt Issuance Costs
DebtIssuanceCosts
300000 USD
CY2012Q4 us-gaap Secured Debt
SecuredDebt
13000000 USD
CY2013Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
25000000 USD
CY2013Q1 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
50000000 USD
CY2013Q1 hbio Ddtl Threshold For Dollar For Dollar Reduction In Revolving Line
DdtlThresholdForDollarForDollarReductionInRevolvingLine
10000000 USD
CY2013Q2 us-gaap Notional Amount Of Interest Rate Derivatives
NotionalAmountOfInterestRateDerivatives
15000000 USD
CY2013Q2 hbio Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed
MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed
0.5
us-gaap Derivative Instruments Gain Loss Reclassification From Accumulated Oci To Income Estimated Net Amount To Be Transferred
DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
100000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.5100
CY2013Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3070
CY2012Q3 us-gaap Assets
Assets
130580000 USD
CY2012Q3 us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD

Files In Submission

Name View Source Status
0001171843-13-004541-index-headers.html Edgar Link pending
0001171843-13-004541-index.html Edgar Link pending
0001171843-13-004541.txt Edgar Link pending
0001171843-13-004541-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10q_110813.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hbio-20130930.xml Edgar Link completed
hbio-20130930.xsd Edgar Link pending
hbio-20130930_cal.xml Edgar Link unprocessable
hbio-20130930_def.xml Edgar Link unprocessable
hbio-20130930_lab.xml Edgar Link unprocessable
hbio-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending